Saturday, August 06, 2016 10:18:00 AM
"LP jumping the gun on the trial investigator"
Yet again, the whole Buzdar issue is spurious when researched just as so many of the hype and speculation posted by some.
NWBO did not receive any "rebuke" from any clinical trial site about this issue [I am sure they would have if it was of such importance] NWBO had previously stated that it would release interim data on an ongoing basis regarding the DCVax-Direct Phase 1/2 clinical trial. The apparent 'disclosed data' originated from medical files sent to the company from the trial sites and a CRO. AF had again purposely attacked NWBO [not for the first time] and yet issuing interim results the way NWBO did is not even unusual for an unblinded open-label study like DCVax. So yet again we see facts are twisted to give sensationalised headlines putting doubt into investors for their own self interests.
Yet again, the whole Buzdar issue is spurious when researched just as so many of the hype and speculation posted by some.
NWBO did not receive any "rebuke" from any clinical trial site about this issue [I am sure they would have if it was of such importance] NWBO had previously stated that it would release interim data on an ongoing basis regarding the DCVax-Direct Phase 1/2 clinical trial. The apparent 'disclosed data' originated from medical files sent to the company from the trial sites and a CRO. AF had again purposely attacked NWBO [not for the first time] and yet issuing interim results the way NWBO did is not even unusual for an unblinded open-label study like DCVax. So yet again we see facts are twisted to give sensationalised headlines putting doubt into investors for their own self interests.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
